Oregon Psilocybin Program Yields Real-World Data, Heidi Overton Tapped to Lead the FDA, and Johnson & Johnson Leads $85 Million Investment Round
Oregon Psilocybin Program Shows Mental Health Improvements Amid Looming Financial Collapse
Oregon’s first-in-the-nation supported psilocybin framework is yielding substantial mental health improvements and high safety ratings, though severe financial deficits now jeopardize the program’s survival. A recent JAMA Network Open study, which received funding from the Substance Abuse and Mental Health Services Administration (SAMHSA), the National Institutes of Health (NIH), and the National Institute on Drug Abuse (NIDA), monitored 346 self-selected, self-reporting clients and found a majority experienced steep drops in depression, anxiety, and post-traumatic stress disorder symptoms three months after receiving care at state-licensed facilities. On June 26, the Oregon Health Authority proposed a doubling of industry licensing fees to offset budget shortfalls, a regulatory shift that industry advocates warn could collapse the legal market.
In a recent interview with Psychedelic State(s) of America, Oregon resident and Center for Psychedelic Policy Founder Sam Chapman acknowledged the shortcomings of Oregon’s pioneering regulated psilocybin services access model.
“The fee-based licensure model is simply not sustainable,” said Chapman. “A primary downside of being first [in the U.S. to create a legal psilocybin services program] is that we lacked a custom playbook, so regulators leaned on cannabis structures.”
“But those frameworks rely on selling physical retail products,” Chapman expounded, “which fundamentally differs from psilocybin’s model. The product here is the service itself, making the current infrastructure inappropriate.”
The impending fee increases threaten to worsen existing socioeconomic disparities within the program, which currently serves a clientele that is predominantly white, affluent, and highly educated. Independent facilitators estimate that the proposed hikes could drive the price of a single psilocybin session up to $3,000, severely limiting affordability and potentially pushing consumers toward unregulated, underground alternatives. While the recent study highlighted a strong safety profile, including zero instances of physical or sexual misconduct and only a 1.2% rate of severe behavioral reaction, it also exposed regulatory reporting gaps, as operators are only required to document adverse events that happen within three days of administration.
Industry experts argue that the state’s financial turmoil stems from mistakenly applying a commercial cannabis regulatory model to a specialized service. The state agency is fighting a civil lawsuit claiming that restricting psilocybin use to licensed centers violates the Americans with Disabilities Act by denying access to terminally ill and homebound clients. The plaintiffs’ legal team contends that allowing at-home administration would not only serve vulnerable populations but also expand the consumer base and improve the program’s overall financial viability. Stakeholders are now looking to public rulemaking hearings in September to secure legislative remedies before the 2027 fee hikes are finalized.
MAHA Ally, Presidential Advisor Heidi Overton Tapped to Lead the FDA
President Donald Trump has nominated White House domestic policy adviser and physician Dr. Heidi Overton to lead the Food and Drug Administration, placing her at the helm of an agency critical to the regulatory pipeline for psychedelic medicines. According to recent reporting in The Atlantic, Overton clashed with the leaders of the ibogaine lobby after leading a Domestic Policy Council interagency review of a new executive order drafted by the Department of Health and Human Services. The order was spurred by a conversation between Trump and podcaster Joe Rogan. Much like marijuana entrepreneurs and Trump friend Howard Kessler, who won rescheduling through direct appeals to the president, The Atlantic reports Rogan followed that playbook on psychedelics. These appeals were designed in part to bypass the interagency process, signaling that psychedelic policy is now moving through personal access rather than standard agency review.
Working alongside the Justice Department and the Veterans Administration, Overton slashed the HHS draft from 1,400 to 900 words, eliminating a proposed psychedelic therapy czar and reducing a $250 million research fund to a $50 million state partnership. These sweeping cuts were heavily influenced by internal government anxieties; officials at the VA were concerned about patients suddenly demanding treatments the department was not ready to provide, highlighting a distinct research-versus-access gap sourced directly from inside the agency. The reductions were initially made without input from Rogan and Americans for Ibogaine CEO W. Bryan Hubbard, who then threatened a boycott of the signing ceremony if they weren’t afforded an opportunity to provide input on the final draft of the order. Ultimately, Rogan and Hubbard attended the Oval Office signing ceremony after securing a compromise that retained provisions to expedite reviews for select drugs and encourage the rescheduling of trial-proven psychedelics.
If confirmed by the Senate to replace former Commissioner Dr. Marty Makary, who resigned in May, Overton will oversee the 18,000-person FDA. Her nomination faces steep bipartisan skepticism over her limited executive management experience and a polarizing public health record, including her opposition to the telehealth distribution of abortion pills and youth transgender medical care, as well as her defense of unbundling standard childhood immunizations, leaving her path to confirmation highly uncertain.
Johnson & Johnson Spearheads $85 Million Series C Fundraising for Delix Therapeutics
As first reported by Psychedelic Alpha, Johnson & Johnson will spearhead an $85 million Series C investment in Delix Therapeutics, placing the neuroplastogen maker’s pre-money valuation at $190 million. Delix focuses on developing neuroplastogens — non-hallucinogenic psychedelic-derived compounds that are designed to trigger beneficial neuroplasticity without an inebriating trip. This strategy aims to circumvent the logistical barriers of traditional psychedelic treatments, which mandate intensive medical supervision and in-clinic administration.
The impending capital injection will propel Delix’s primary drug candidate, DLX-001, into Phase 2 clinical trials. Modeled after the psychedelic compound 5-MeO-DMT, the drug (also known as zalsupindole) appeared to show fast-acting and prolonged antidepressant properties in a limited Phase 1b trial targeting a cohort of 18 participants with major depressive disorder. The Food and Drug Administration has authorized the framework for the Phase 2 trial, which will test self-administered, at-home dosing on either a daily or twice-a-week regimen.
While the full financing has not yet closed, this prospective investment marks big pharma’s growing footprint in the psychedelic medicine sector. Johnson & Johnson already navigates this market with Spravato, an esketamine-based nasal spray that requires strict clinical oversight. Under the proposed financing agreement, Johnson & Johnson will secure the right of first negotiation to acquire the DLX-001 program or buy Delix outright once the Phase 2 trial results become available.
This article was produced in partnership with Psychedelic State(s) of America – a nonprofit-sponsored news organization dedicated to rigorous independent psychedelic journalism. Learn more about PSA’s Media Partnerships Program and donate to the PSA Media Fund here.
